GLP-1 Therapies Newsletter
Issue #32April 13, 20267 studies

60% of weight lost on GLP-1 drugs returns within a year of stopping

GLP-1 drugs like semaglutide and tirzepatide have transformed obesity treatment, but what happens when people stop taking them? This week's research reveals the predictable pattern of weight regain, explores new combination therapies, and examines both promising benefits and unexpected side effects of these blockbuster medications.

📈 Weight Regain Follows Predictable Pattern After Stopping GLP-1 Drugs

  • Researchers analyzed 48 studies involving patients who stopped GLP-1 receptor agonists and found that 60% of weight lost during treatment returned within one year

  • The weight regain followed a predictable mathematical curve, with a half-life of 23 weeks—meaning half the total regain happened in about 5-6 months

  • Weight appeared to plateau at 75% regain of original losses, suggesting some long-term benefit may persist even after discontinuation

Why it matters: These findings provide the first quantitative model for predicting weight regain after GLP-1 discontinuation, helping doctors and patients make informed decisions about long-term treatment planning.

🥈 Top 2% journal 🔗 EClinicalMedicine Journal Article 🗓️ Apr 6

Key Findings

🍽️ GLP-1 Drugs Show Promise for Binge Eating Disorder

  • A systematic review of 12 studies found that GLP-1 receptor agonists consistently reduced binge eating behaviors across different measures

  • Patients experienced significant weight loss ranging from 3 to 24 kg, with improvements in blood sugar control

  • Side effects were primarily gastrointestinal, with no new psychiatric safety concerns identified

💡 These drugs may offer a dual benefit for people struggling with both binge eating and obesity-related health problems.
🔗 Pharmacotherapy Systematic Review 🗓️ Apr 8

💊 Combining Two Drug Classes Beats Solo Treatment for Kidney Protection

  • Analysis of 8 trials with 1,974 patients showed that combining GLP-1 drugs with SGLT2 inhibitors significantly reduced kidney damage markers compared to either drug alone

  • The combination was particularly effective at lowering protein in urine, a key sign of kidney disease progression

  • Benefits remained significant when compared to SGLT2 inhibitors alone but not when compared to GLP-1 drugs alone

💡 Early combination therapy could provide superior kidney protection for people with diabetes at high risk of kidney disease.
🔗 Pharmacotherapy Systematic Review 🗓️ Apr 8

🧬 Genetic Variants Predict Who Responds Best to GLP-1 Medications

  • Study of 27,885 people found a genetic variant in the GLP-1 receptor gene linked to an additional 0.76 kg of weight loss per copy of the beneficial variant

  • Researchers identified genetic associations with nausea and vomiting side effects, with different patterns for semaglutide versus tirzepatide

  • The findings enable stratifying patients by both expected effectiveness and side effect risk

💡 Genetic testing could eventually help doctors personalize GLP-1 treatment by predicting who will see the best results with fewest side effects.
🔗 Nature Journal Article 🗓️ Apr 8

🏥 Real-World Study Shows Tirzepatide Outperforms Other GLP-1 Drugs

  • Comparison of 282 Indian adults with obesity found tirzepatide achieved greater weight loss than semaglutide or liraglutide after 24 weeks

  • 90% of tirzepatide users achieved at least 5% weight loss, compared to lower rates with other drugs

  • Gastrointestinal side effects were most common with liraglutide, while tirzepatide was generally well-tolerated

💡 In head-to-head comparisons, tirzepatide's dual-receptor approach appears to deliver superior weight loss with acceptable side effects.
Top 30% journal 🔗 Diabetes, metabolic syndrome and obesity : targets and therapy Journal Article 🗓️ Apr 6

🔬 Mouse Brain Atlas Reveals Sex Differences in GLP-1 System

  • Detailed mapping of GLP-1-producing neurons in mouse brains found higher concentrations in key brain regions of females compared to males

  • Female mice had more GLP-1 neurons in areas controlling appetite and blood sugar regulation, which may explain why women often respond better to these medications

  • The atlas provides a foundation for understanding why GLP-1 drugs show stronger effects on appetite and weight loss in females

💡 Sex differences in brain GLP-1 systems may help explain why these medications work differently in men and women.

⚠️ Tirzepatide Users Show Lower Heart Failure Reports in Safety Database

  • Analysis of 103,693 tirzepatide reports in FDA's safety database found 82% lower odds of heart failure reports compared to other drugs

  • No increased reporting of heart attacks, chest pain, or irregular heartbeats was detected when focusing on healthcare professional reports

  • The findings complement ongoing cardiovascular outcome trials by providing real-world safety signals

💡 Early safety data suggests tirzepatide may have cardiovascular benefits beyond its metabolic effects, though definitive trials are still ongoing.
Top 20% journal 🔗 Frontiers in pharmacology Journal Article 🗓️ Apr 8

Implications

This week's research paints a nuanced picture of GLP-1 drugs: they're powerful tools with predictable limitations. While weight regain after discontinuation appears inevitable, genetic factors may help identify who benefits most, and combination approaches could maximize benefits for kidney and metabolic health. The emerging safety profile looks encouraging, but the medications' effects extend far beyond weight loss into areas like binge eating and even brain function differences between sexes.

Studies in this issue

Primary sources used for this newsletter.

  1. Patterns of weight regain after stopping GLP-1 receptor agonist treatment
    main storyEClinicalMedicine2026-04-06PMID 41938838
  2. Heart-related problems reported with tirzepatide: real-world data on heart failure, irregular beats, and blood flow blockages
    key findingFrontiers in pharmacology2026-04-08PMID 41948731
  3. Genetic factors linked to weight loss and side effects from GLP-1 receptor drugs
    key findingNature2026-04-08PMID 41951734
  4. Map of GLP-1 in the mouse brain linked to metabolism and mental health
    key findingBrain medicine : from neurons to behavior and better health2026-04-09PMID 41953414
  5. Better Kidney Health from Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors Compared to Using One Alone
    key findingPharmacotherapy2026-04-08PMID 41947610
  6. Incretin-Based Treatments for Binge Eating: A Systematic Review
    key findingPharmacotherapy2026-04-08PMID 41947645
  7. Effectiveness and Safety of Three Weight-Loss Drugs in Adults with Overweight or Obesity Without Diabetes
    key findingDiabetes, metabolic syndrome and obesity : targets and therapy2026-04-06PMID 41938643

Continue reading

All GLP-1 Therapies issues